Skip to main content
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy

Open Access 02-07-2025 | Artificial Intelligence | COMMENTARY

Selecting the Right AI Algorithm for the Job: A Guide for Navigating the AI Jungle in Ophthalmology

Authors: Louis Arnould, Atif Anwer, Andrzej Grzybowski, Fabrice Meriaudeau

Published in: Ophthalmology and Therapy

Login to get access

Excerpt

Understanding how to choose the right artificial intelligence (AI) algorithm is essential for ophthalmologists to navigate the AI jungle—improving their ability to critically assess the literature, stimulate their research project, and evaluate industry-proposed tools.
This article provides a practical framework to help ophthalmologists select, evaluate, and implement AI tools suited to their specific needs.
Successful integration of AI in ophthalmology requires close collaboration between clinicians, data scientists, Information Technology professionals, and research methodologists.
Open-source datasets are highlighted as valuable resources for ophthalmologists to benchmark algorithms, ensure reproducibility, and support local development when large annotated datasets are lacking.
A decision-making checklist is proposed to guide the safe and effective adoption of AI tools, taking into account clinical relevance, validation, performance metrics, and regulatory context.
…
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Selecting the Right AI Algorithm for the Job: A Guide for Navigating the AI Jungle in Ophthalmology
Authors
Louis Arnould
Atif Anwer
Andrzej Grzybowski
Fabrice Meriaudeau
Publication date
02-07-2025
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-025-01191-2

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more
Image Credits